Outcomes of Subtotal Colectomy with Ileorectal Anastomosis and Intensive Endoscopic Surveillance in Familial Adenomatous Polyposis: A Case Series Authors: Chi-Han Yang, Hsiang-Lin Tsai, Yen-Cheng Chen, Po-Jung Chen, Tsung-Kun Chang, Wei-Chih Su, Ching-Wen Huang, Jaw-Yuan Wang Published: 2026 ABSTRACT BackgroundFamilial adenomatous polyposis (FAP) is an inherited disorder caused by mutations in the adenomatous polyposis coli gene, causing numerous colorectal adenomas to develop. If left untreated, FAP is associated with a nearly 100% lifetime risk of colorectal cancer. Subtotal colectomy with ileorectal anastomosis (IRA) is a surgical option that preserves rectal function but necessitates intensive postoperative surveillance due to the residual risk of malignancy in the retained rectum.MethodsThis small retrospective case series included seven patients with FAP who underwent subtotal colectomy with IRA at a single institution between 2015 and 2024. Postoperative management involved intensive colonoscopic surveillance and polypectomy of rectal lesions. Additionally, the exploratory use of adjunctive silymarin was recorded. Clinical and pathological data were analyzed, including the incidence of residual rectal polyps, bowel function, and clinical outcomes.ResultsOver a median follow-up of 38.0 months, six of the seven patients developed residual rectal polyps during follow-up, which were successfully removed through polypectomy without evidence of malignant transformation. Bowel function was well-preserved in all patients, with rectal lengths ranging from 10 to 15 cm. Silymarin, a natural polyphenolic flavonoid with potential chemopreventive effects, was administered to six of the seven patients, among whom it was well-tolerated. The long-term effects of silymarin are under evaluation during ongoing follow-up.ConclusionSubtotal colectomy with IRA, combined with regular colonoscopic surveillance and timely polypectomy, demonstrates short-term feasibility and may be an effective management strategy in selected patients for preserving bowel function. The exploratory use of silymarin was well-tolerated; however, its clinical efficacy remains strictly hypothesis-generating and further clinical trials are needed to validate its safety and potential role in human populations. These findings highlight the necessity of individualized surgical planning and vigilant long-term surveillance in FAP management. Background Familial adenomatous polyposis (FAP) is an inherited disorder caused by pathogenic mutations in the adenomatous polyposis coli (APC) gene, which disrupts regulation of the Wnt/β-catenin signaling pathway and drives the formation of colorectal adenomas. Affected individuals typically develop hundreds to thousands of adenomas during adolescence, which are associated with a nearly 100% lifetime risk of colorectal cancer (CRC) if left untreated. In addition to colorectal polyps, FAP is associated with extracolonic manifestations, including duodenal adenomas, desmoid tumors, and malignancies in other organs, such as the stomach and thyroid.1 FAP management typically involves either ileorectal anastomosis (IRA) or ileal pouch-anal anastomosis (IPAA). IRA preserves rectal function, is associated with fewer postoperative complications, and generally results in better quality of life than IPAA. However, IRA requires lifelong endoscopic surveillance due to the continued risk of rectal cancer from residual mucosa. By contrast, IPAA is a more complex procedure that eliminates the risk of CRC through the removal of all colorectal mucosa that is associated with higher rates of bowel dysfunction and other complications, potentially affecting long-term functional outcomes.2 The British Society of Gastroenterology recommends total colectomy with IRA for patients with relative rectal sparing, defined as fewer than 20 rectal polyps, particularly when adenomas are less than 5 mm in diameter or when larger polyps are amenable to endoscopic resection. These guidelines emphasize that surgical decision-making should account for the rectal polyp burden, associated cancer risk, and the patient’s ability and willingness to adhere to long-term endoscopic surveillance.3 While current guidelines outline general surveillance strategies after IRA, real-world data evaluating the outcomes of highly intensive colonoscopic monitoring, as well as the potential role of adjunctive chemoprevention, remain limited. Therefore, the objective of this descriptive case series was to evaluate short-term clinical outcomes, including bowel function and rectal polyp recurrence, in seven patients with FAP who underwent subtotal colectomy with IRA. Furthermore, to address the ongoing risk of neoplasia, we report on the exploratory, strictly hypothesis-generating use of silymarin as an adjunctive chemopreventive agent in this cohort. Materials and Methods Case Presentation Between 2015 and 2024, seven patients diagnosed with FAP or related polyposis syndromes were treated at our institution (Table 1). The inclusion criteria for this retrospective study were: (1) a clinical or genetic diagnosis of FAP, (2) availability of postoperative colonoscopic surveillance records. Patients who did not receive surgical treatment were excluded. To minimize selection bias, all consecutive patients meeting these criteria during the study period were included in this cohort. The cohort included four males and three females, with a median age of 24 years (range: 20–63 years) at the time of diagnosis.Table 1Clinical and Pathological Characteristics of Seven Patients with Familial Adenomatous PolyposisCaseSexAge of DiagnosisDate of DiagnosisInitial ManifestationsColonoscopy FindingBiopsy PathologyOperation DateOperation MethodPathologic ReportRemained RectumLength (cm)Total PolypectomiesPostoperative PathologyFollow-Up Duration (Month)Silymarin Use1M22August 2015Frequent diarrheaMultiple colon polyp over entire colon till rectumTubular adenomaOctober 2020Subtotal colectomy with IRATubular adenoma107Tubular adenoma, low grade dysplasia66Yes2M46March 2017Chronic anemiaMultiple polyps lesion over entire colon till rectum; one malignant lesion in sigmoid colonTubular adenoma; adenocarcinomaApril 2017Subtotal colectomy with IRASigmoid colon adenocarcinoma, pT2N0M0, stage 1152Tubular adenoma, low grade dysplasia60No3F26February 2022AsymptomaticMultiple polyps over entire colon till rectumTubular adenomaApril 2022Subtotal colectomy with IRATubular adenoma155Tubular adenoma, low grade dysplasia48Yes4F23March 2023AsymptomaticMultiple polyps from transverse colon to rectumTubular adenomaApril 2023Subtotal colectomy with IRATubular adenoma153Tubular adenoma, low grade dysplasia36Yes5M20February 2023Abdominal pain and bloody stoolMultiple polyps over entire colon to rectumTubular adenomaFebruary 2023Subtotal colectomy with IRATubular adenoma104Tubular adenoma, low grade dysplasia38Yes6M63March 2023Abdominal pain and bloody stoolMultiple colon polyp over entire colon; one malignant lesion in ascending colonTubular adenoma; adenocarcinomaMarch 2023Subtotal colectomy with IRAAscending colon adenocarcinoma, pT3N0M0, stage IIA150Unremarkable37Yes7F24July 2024Abdominal pain and vomitingMultiple colon polyp over entire colon till rectumTubulovillous adenomaNovember 2024Subtotal colectomy with IRATubular adenoma101Tubular adenoma, low grade dysplasia17YesNotes: Total polypectomies refers to the cumulative number of polyps resected during the colonoscopic surveillance period.Abbreviation: IRA, ileorectal anastomosis. Table 1Clinical and Pathological Characteristics of Seven Patients with Familial Adenomatous PolyposisCaseSexAge of DiagnosisDate of DiagnosisInitial ManifestationsColonoscopy FindingBiopsy PathologyOperation DateOperation MethodPathologic ReportRemained RectumLength (cm)Total PolypectomiesPostoperative PathologyFollow-Up Duration (Month)Silymarin Use1M22August 2015Frequent diarrheaMultiple colon polyp over entire colon till rectumTubular adenomaOctober 2020Subtotal colectomy with IRATubular adenoma107Tubular adenoma, low grade dysplasia66Yes2M46March 2017Chronic anemiaMultiple polyps lesion over entire colon till rectum; one malignant lesion in sigmoid colonTubular adenoma; adenocarcinomaApril 2017Subtotal colectomy with IRASigmoid colon adenocarcinoma, pT2N0M0, stage 1152Tubular adenoma, low grade dysplasia60No3F26February 2022AsymptomaticMultiple polyps over entire colon till rectumTubular adenomaApril 2022Subtotal colectomy with IRATubular adenoma155Tubular adenoma, low grade dysplasia48Yes4F23March 2023AsymptomaticMultiple polyps from transverse colon to rectumTubular adenomaApril 2023Subtotal colectomy with IRATubular adenoma153Tubular adenoma, low grade dysplasia36Yes5M20February 2023Abdominal pain and bloody stoolMultiple polyps over entire colon to rectumTubular adenomaFebruary 2023Subtotal colectomy with IRATubular adenoma104Tubular adenoma, low grade dysplasia38Yes6M63March 2023Abdominal pain and bloody stoolMultiple colon polyp over entire colon; one malignant lesion in ascending colonTubular adenoma; adenocarcinomaMarch 2023Subtotal colectomy with IRAAscending colon adenocarcinoma, pT3N0M0, stage IIA150Unremarkable37Yes7F24July 2024Abdominal pain and vomitingMultiple colon polyp over entire colon till rectumTubulovillous adenomaNovember 2024Subtotal colectomy with IRATubular adenoma101Tubular adenoma, low grade dysplasia17YesNotes: Total polypectomies refers to the cumulative number of polyps resected during the colonoscopic surveillance period.Abbreviation: IRA, ileorectal anastomosis. Clinical and Pathological Characteristics of Seven Patients with Familial Adenomatous Polyposis Notes: Total polypectomies refers to the cumulative number of polyps resected during the colonoscopic surveillance period. Abbreviation: IRA, ileorectal anastomosis. Patients 1, 2, and 7 had a documented family history of FAP and CRC. Patients 3, 4, and 5 were siblings with a familial history of FAP and colorectal malignancy. In all patients, colonoscopy revealed more than 100 colorectal polyps of varying number and histopathological characteristics. Most patients presented with diarrhea, anemia, abdominal pain, or hematochezia; however, one case was identified incidentally during routine screening. Histopathological analysis predominantly revealed tubular adenomas, with tubulovillous adenomas or adenocarcinoma observed in several patients. Surgical management typically involved resection up to the rectosigmoid junction; however, in cases with substantial rectal involvement, resection was extended to include the upper rectum. This retrospective review highlights the heterogeneous clinical and colonoscopic features of FAP, underscoring the need for individualized surgical strategies based on the extent of rectal disease. Three of the seven patients underwent genetic testing for APC mutations based on clinical indications and informed consent. Germline testing was performed for all three individuals using a targeted multi-gene panel provided by Invitae (San Francisco, CA, USA). Genomic DNA was extracted from peripheral blood samples, enriched for target regions through a hybridization-based protocol, and sequenced on an Illumina platform. Sequence reads were aligned to the GRCh37 human genome reference, and variant analysis was conducted with respect to clinically relevant transcripts. The assay detected single nucleotide variants, small insertions and deletions, and exon-level deletions and duplications, with a minimum sequencing depth of 50× across all targeted regions. Distinct APC mutations were identified in all three patients tested, including a point mutation in exon 15 (c.5465T>A) in patient 1, a deletion mutation in exon 16 (c.3183_3187del) in patient 3, and a promoter region variant (c.-30266G>A) in patient 6. This study involving human participants was reviewed and approved by the Institutional Review Board of Kaohsiung Medical University Hospital, Taiwan (approval no. KMUHIRB-E(I)-20230267), and written informed consent was obtained from all patients. Surgical Intervention and Postoperative Follow-Up All seven patients underwent subtotal colectomy with ileorectal side-to-end anastomosis and subsequently completed intensive colonoscopic surveillance during follow-up. The decision to perform IRA rather than IPAA was individualized for each patient through shared decision-making. Key criteria favoring IRA in this cohort included a manageable rectal polyp burden, strong patient preference for preserving bowel function and continence, and fertility considerations, particularly for younger female patients. Furthermore, the absence of severe comorbidities and the surgeon’s judgment regarding the technical feasibility of preserving the rectum while maintaining oncologic safety were critically evaluated. The surveillance strategy recommended under the 2024 clinical guidelines issued by the European Society of Coloproctology and the American Society of Colon and Rectal Surgeons (ASCRS) involves endoscopic monitoring every 6–12 months following IRA. In our clinical practice, we adopted a more rigorous protocol and conducted colonoscopies every 3–6 months during the initial 2 years postoperatively. Thereafter, colonoscopies were conducted every 6–12 months depending on the number, size, and histopathological features of previously identified adenomas. To ensure procedural consistency, all surveillance colonoscopies were performed by a dedicated team of experienced endoscopists using high-definition colonoscopes. Standardized bowel preparation protocols were strictly followed prior to each procedure. Polypectomy strategies were uniform across the cohort, utilizing cold snare polypectomy for diminutive lesions and hot snare or endoscopic mucosal resection for larger adenomas to ensure complete excision. Postoperative colonoscopic evaluation enabled us to document the length of the remaining rectum and colon and perform biopsies and histopathological examinations when rectal polyps were identified. During outpatient visits, daily bowel movement frequency was recorded, and patients were monitored for any postoperative complications. All patients adhered to the surveillance protocol during the initial postoperative period. Patient 2 was lost to follow-up 5 years after surgery, and the remaining 6 patients continued to receive active surveillance at our institution. As part of an exploratory institutional practice for chemoprevention, six of the seven patients were prescribed oral silymarin (150 mg three times daily)4 following surgery. Because this was a retrospective, observational cohort rather than a prospective clinical trial, there was no formalized protocol for dose titration, predefined duration of treatment, or strict adherence monitoring. Silymarin was administered solely on an empirical, hypothesis-generating basis driven by its favorable safety profile. No statistical analyses were performed in this study, as it is a descriptive retrospective case series involving a small number of patients. Results During the first 2 years following surgery, follow-up colonoscopies were scheduled approximately every 3–6 months for each patient. Subsequent surveillance intervals were individualized based on the number and characteristics of polyps detected during prior examinations, with most patients undergoing colonoscopy every 6 months. Polypectomy was performed whenever rectal polyps were identified. Six of the seven patients developed residual rectal polyps postoperatively and underwent endoscopic polypectomy. Histopathological analysis confirmed low-grade dysplasia in all resected polyps. The median follow-up duration for the cohort was 38.0 months (range: 17–66 months). To date, no malignant adenomas or cancerous lesions have been detected in the residual rectum of any patient. The average length of the remaining rectum in the seven patients ranged from approximately 10–15 cm. During postoperative outpatient follow-up, patients reported an average of 3–5 bowel movements per day, with no episodes of fecal or flatus incontinence observed. We identified several FAP-associated tumors in our patients, highlighting the extracolonic manifestations of this disease. Patient 2 developed multifocal papillary thyroid microcarcinomas in 2021, 4 years after the initial FAP diagnosis, and subsequently underwent total thyroidectomy followed by radioiodine ablation therapy. Patient 3 was diagnosed with papillary thyroid carcinoma in 2021, 1 year before FAP diagnosis, and was treated with left total and right subtotal thyroidectomy in December 2021. In Patient 7, a mucinous cystadenoma of the pancreatic tail and a fundic gland polyp in the stomach were identified several months before FAP diagnosis; this patient underwent distal pancreatectomy and partial gastrectomy in July 2024. These cases underscore the necessity of comprehensive and multidisciplinary surveillance in patients with FAP, because this condition increases the risk of a broad spectrum of extracolonic neoplasms that require timely detection and management. The seven participating patients completed postoperative follow-up between April 2017 and April 2026. At the final follow-up appointment, no case of rectal cancer had been detected. All patients except for patient 2 received silymarin as a chemopreventive agent. Although most evidence supporting the role of silymarin in preventing CRC and polyp formation has been derived from preclinical animal studies, its favorable safety profile prompted its exploratory administration as an institutional practice in this cohort. Patients underwent long-term monitoring to observationally record any potential effects of silymarin on clinical outcomes, though no definitive conclusions regarding efficacy can be drawn from this small, uncontrolled series. In ongoing outpatient follow-up, rectal polyp status, colonoscopic polypectomy (when indicated), and bowel movement patterns continue to be assessed. Discussion The seven patients with FAP underwent subtotal colectomy with side-to-end IRA, preserving approximately 10–15 cm of rectum. During postoperative follow-up, rectal polyps were detected in six of the seven patients. Intensive surveillance colonoscopies and timely polypectomies prevented progression to rectal cancer in all six of these patients as of April 2026. These findings suggest that when combined with diligent endoscopic surveillance, subtotal colectomy with IRA is a viable treatment option for patients with FAP and no rectal malignancy at the time of surgery. Surveillance protocols were informed by the 2024 guidelines from the European Society of Coloproctology and the ASCRS, which recommend endoscopic follow-up every 6–12 months after IRA; however, we employed a more intensive schedule consisting of colonoscopies every 3–6 months during the first 2 postoperative years, followed by colonoscopies every 6–12-months based on individualized adenoma burden and histopathological findings.1,5 Further studies involving larger patient cohorts and longer follow-up periods are necessary to strengthen the available evidence. Among studies in the literature, Tajika et al analyzed 84 patients with FAP who underwent surgical treatment between 1965 and 2019, including 22 treated with IPAA and 12 with IRA. Adenoma development was observed in 94.1% of patients; however, no instances of adenocarcinoma were reported, and no additional surgeries were required during the follow-up period.6 Both the IPAA and IRA groups underwent intensive annual and 6-month endoscopic surveillance, respectively, during the follow-up. The findings of this previous retrospective study highlight that adenomas can develop following both IRA and IPAA. As such, postoperative endoscopic surveillance is essential for all patients, and those undergoing IRA require more frequent monitoring due to the retained rectal mucosa. Both the Clinical Practice Guidelines of the ASCRS and findings from a recent systematic review indicate that colonoscopy should be performed every 6–12 months for patients who have received IRA.5 A meta-analysis demonstrated that IRA results in superior bowel function compared with IPAA. Patients who underwent IRA reported fewer daily bowel movements, lower rates of nighttime defecation, and a lower incidence of fecal incontinence than those who underwent IPAA. Moreover, IRA was associated with fewer social restrictions (4% vs. 14%) and comparable rates of sexual dysfunction and dietary limitations to IPAA. These functional advantages make IRA a compelling surgical option for patients with FAP and a limited rectal polyp burden, particularly those who prioritize the preservation of bowel function and quality of life.7 Consistent with our cohort, the selection of IRA was heavily influenced by the need to balance oncologic safety with continence expectations and fertility concerns, emphasizing the necessity of a highly personalized surgical approach. Maehata et al retrospectively analyzed 27 patients with FAP who underwent IRA between 1990 and 2004. During the follow-up period, 10 patients developed rectal cancer (37.0%), indicating a substantial risk of cancer in the rectal remnant (CRR) following IRA.8 The cumulative incidence of CRR following IRA has been reported as 8%, 19%, and 57% at 10, 20, and 30 years, respectively. Although IRA is technically less complex than IPAA, it is associated with a significantly higher long-term risk of CRR, particularly without rigorous postoperative surveillance. Therefore, individualized, long-term monitoring is critical to ensure early detection and timely management of CRR, especially in high-risk patients, given that the risk of malignant transformation increases substantially over time. In a separate retrospective analysis of 37 patients with FAP, Sasaki et al reported that although IRA was associated with a higher incidence of rectal cancer compared with IPAA, it offered superior preservation of anal function, supporting its use in carefully selected patients with a limited rectal polyp burden to maintain bowel function and quality of life.9 Nevertheless, the risk of metachronous rectal cancer increases over time, underscoring the need for intensive endoscopic surveillance.10 Previous animal studies have demonstrated that silymarin, a polyphenolic flavonoid derived from milk thistle (Silybum marianum), possesses promising chemopreventive properties against CRC.11 In azoxymethane-treated rats, silymarin reduced aberrant crypt foci and colonic adenocarcinomas by increasing detoxifying enzymes and lowering β-glucuronidase and prostaglandin E2 levels. In APCmin/+ mice, silymarin inhibited microbial β-glucuronidase, preventing dysbiosis and tumor formation.12 These findings suggest that silymarin can modulate gut microbiota and tumorigenic pathways, warranting further clinical research. Therefore, in addition to close colonoscopic surveillance, we administered silymarin to all patients except patient 2 on a strictly exploratory basis. We emphasize that the use of silymarin in this study is hypothesis-generating, and its therapeutic efficacy cannot be established from our limited dataset. Although current evidence supporting the use of silymarin to prevent CRC and polyps is primarily derived from animal models, previous clinical studies have demonstrated its favorable safety profile and its potential to reduce gastrointestinal toxicities in patients with metastatic colorectal cancer.4 This evidence prompted us to administer silymarin under close monitoring of patients’ long-term clinical outcomes. We anticipate that future studies with more robust clinical data can contribute to validating the efficacy of silymarin in this context; the current lack of such data remains a major limitation. Prospective, multicenter randomized controlled trials are needed to evaluate the efficacy, optimal dosing, safety, and long-term outcomes of silymarin in patients at high risk of CRC and polyps. Biomarker-guided approaches may elucidate the role of silymarin in precision chemoprevention strategies. The small sample size, single-center design, absence of a comparator group (such as patients undergoing IPAA), and relatively short follow-up period of our study precluded comprehensive long-term risk assessment and may limit the generalizability of our findings. Consequently, this study should be interpreted strictly as an exploratory and descriptive case series. Our findings are intended to provide preliminary observational experience rather than definitive evidence of therapeutic efficacy. Additionally, only three of the seven patients included consented to genetic testing. Furthermore, bowel function and quality of life were evaluated based on subjective patient reports during clinical visits rather than through validated functional instruments, which may introduce reporting bias. Given that patients with FAP—particularly those under 30 years of age—require lifelong surveillance to monitor disease progression and prevent malignant transformation, the limited follow-up duration in this study further restricted the evaluation of long-term outcomes. To improve FAP management and surveillance strategies, future studies should include larger, multicenter cohorts, expansive genetic analyses, and direct comparisons between IRA and IPAA, and the routine use of validated quality-of-life and bowel function instruments. Conclusion This study demonstrated that subtotal colectomy with IRA, when combined with intensive endoscopic surveillance, shows short-term feasibility in managing FAP by preserving rectal function and enabling timely detection and treatment of adenomas. However, the absence of rectal cancer in this cohort should not be interpreted as evidence of long-term oncologic safety. Given the higher long-term risk of rectal cancer associated with IRA compared with IPAA, sustained surveillance remains essential. Further multicenter studies and direct comparative analyses between IRA and IPAA are warranted to optimize surgical decision-making and long-term management strategies for patients with FAP.